Form 4: Altimmune CFO Granted Equity Compensation

Altimmune's Chief Financial Officer, Gregory L. Weaver, received grants of 259,000 stock options and 111,000 Restricted Stock Units.

Summary

• Gregory L. Weaver, Chief Financial Officer of Altimmune, Inc. (ALT), was granted 259,000 stock options on February 26, 2026.
• The stock options have an exercise price of $4.46 per share and expire on February 26, 2036.
• The options vest over four years, with 25% vesting on February 26, 2027, and the remainder vesting in equal monthly installments over the subsequent 36 months, contingent on continued service.
• Mr. Weaver also received a grant of 111,000 Restricted Stock Units (RSUs) on February 26, 2026.
• Each RSU represents a contingent right to receive one share of Altimmune Common Stock upon vesting.
• The RSUs vest over four years, with 25% vesting on February 26, 2027, and the remainder vesting in equal annual installments over the following three years, subject to continued service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive, routine event. It signifies continued executive commitment and aligns management's financial interests with the company's long-term performance, which is generally favorable for shareholders.

Positives

• The equity grants align the Chief Financial Officer's interests with those of shareholders, incentivizing long-term performance.
• The grants serve as a retention mechanism for key management personnel.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that the granting of stock options and Restricted Stock Units is a standard practice in the biotechnology and pharmaceutical industry for executive compensation, aiming to attract, retain, and motivate key personnel by linking their incentives to the company's long-term stock performance.

Comparison to Industry Standards

• Equity compensation, including stock options and RSUs, is a common component of executive pay packages across the biotech sector, comparable to practices at companies like Moderna or BioNTech, which frequently use such incentives to align management with shareholder value creation.

Stakeholder Impact

• Shareholders: The equity grants align the Chief Financial Officer's financial incentives with shareholder value creation, potentially leading to more focused long-term strategic decisions.

Next Steps

• Continued vesting of stock options and Restricted Stock Units according to the specified schedules, contingent on Mr. Weaver's continued service.

Key Dates

Keywords

Altimmune, ALT, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, RSU, Equity Compensation, Gregory Weaver, CFO